Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (241-250 of 356) with videos related to

Pageof 36
Sort By:
Diagnostics (Basel, Switzerland)|September 5, 2020
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist InvolvementEnrico De Lorenzis, Silvia Laura Bosello, Francesco Varone, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trialJustin M Oldham, Arata Azuma, Michael Kreuter, et al.
Radiology|June 14, 2014
Idiopathic pulmonary fibrosis: CT and risk of deathBrett Ley, Brett M Elicker, Thomas E Hartman, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|June 22, 2026
Bone involvement in sarcoidosis: Insights from a multicentre Italian cohortTommaso Pianigiani, Elisa Bianchi, Giulio Natalello, et al.
The European Respiratory Journal|May 25, 2019
The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosisVincent Cottin, Isabella Annesi-Maesano, Andreas Günther, et al.
Archivos De Bronconeumologia|December 3, 2025
Impact of Dosing on Functional and Clinical Outcomes of Patients With Progressive Pulmonary Fibrosis Treated With Nintedanib: Data From a Real-World, Multicentric, Italian StudyJacopo Cefalo, Francesco Varone, Fabrizio Luppi, et al.
Thorax|March 20, 2012
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosisLuca Richeldi, Christopher J Ryerson, Joyce S Lee, et al.
BMJ Open Respiratory Research|August 19, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
Respirology (Carlton, Vic.)|August 21, 2023
A randomized trial of pamrevlumab in patients with COVID-19 pneumoniaGiacomo Sgalla, Paolo Maria Leone, Gina Gualano, et al.
Internal and Emergency Medicine|May 27, 2020
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosisElisabetta Cocconcelli, Roberto Tonelli, Gianluca Abbati, et al.
Pageof 36

Showing results (241-250 of 356) with videos related to

Sort By:
Pageof 36
Diagnostics (Basel, Switzerland)|September 5, 2020
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist InvolvementEnrico De Lorenzis, Silvia Laura Bosello, Francesco Varone, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trialJustin M Oldham, Arata Azuma, Michael Kreuter, et al.
Radiology|June 14, 2014
Idiopathic pulmonary fibrosis: CT and risk of deathBrett Ley, Brett M Elicker, Thomas E Hartman, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|June 22, 2026
Bone involvement in sarcoidosis: Insights from a multicentre Italian cohortTommaso Pianigiani, Elisa Bianchi, Giulio Natalello, et al.
The European Respiratory Journal|May 25, 2019
The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosisVincent Cottin, Isabella Annesi-Maesano, Andreas Günther, et al.
Archivos De Bronconeumologia|December 3, 2025
Impact of Dosing on Functional and Clinical Outcomes of Patients With Progressive Pulmonary Fibrosis Treated With Nintedanib: Data From a Real-World, Multicentric, Italian StudyJacopo Cefalo, Francesco Varone, Fabrizio Luppi, et al.
Thorax|March 20, 2012
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosisLuca Richeldi, Christopher J Ryerson, Joyce S Lee, et al.
BMJ Open Respiratory Research|August 19, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
Respirology (Carlton, Vic.)|August 21, 2023
A randomized trial of pamrevlumab in patients with COVID-19 pneumoniaGiacomo Sgalla, Paolo Maria Leone, Gina Gualano, et al.
Internal and Emergency Medicine|May 27, 2020
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosisElisabetta Cocconcelli, Roberto Tonelli, Gianluca Abbati, et al.
Pageof 36